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1 Summary 
 
Introduction Only free drugs can cause pharmacological effects and can be 
metabolized and excreted but the binding to plasma proteins is usually only studied for 
therapeutic drugs. However, for prediction of drug-drug interaction or estimation of 
metabolic stability this parameter is of importance. Thus, this study aims to develop an 
easy and quick procedure to determine the plasma protein binding of drugs of abuse, 
particularly of new psychoactive substances.  
 
Methods The degree of plasma protein binding was determined using ultrafiltration and 
liquid chromatography-mass spectrometry (LC-MS) analysis of the unbound fraction.  
Millipore Centrifree two-chambered devices with a semipermeable membrane were 
used for ultrafiltration. An Agilent MSD was used for MS analysis after separation by 
reversed phase LC. Sample preparation after centrifugation consisted of dilution and 
protein precipitation using acetonitrile. Codeine was added as an internal standard for 
all analytes. Chromatographic separation was achieved using a gradient elution of 
ammonium formate buffer and acetonitrile. Determination of PPB was then carried out 
by analysis of at least six replicates at analyte concentration of 5 µM prior and after 
ultrafiltration. Linear calibration curves using concentration levels from 1-5 µM were 
prepared in plasma and ultrafiltrate and processed as described above.       
                                
Results Plasma protein binding has successfully been determined for 15 NPS 
representing four different classes (synthetic cathinones, synthetic cannabinoids, 
research chemicals and herbal drugs). Values reached from 67% for benzedrone to 
>99% for WIN 55,212-2. Due to the importance of the free and bound ratio of drugs in 
human blood, this method can serve as a fast and reliable technique for determination 
of their plasma protein binding in forensic and clinical toxicology. 
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2 Zusammenfassung 
 
Einleitung: Nur der ungebundene Anteil eines Stoffes ist pharmakologisch wirksam 
und kann im Körper metabolisiert und ausgeschieden werden. In der Literatur 
existieren grundsätzlich vorwiegend Daten über die Plasmaproteinbindung für 
Arzneistoffe. Dabei ist die Plasmaproteinbindung gerade zur Beurteilung der 
metabolischen Stabilität eines Stoffes und dessen Wechselwirkungen mit anderen 
Substanzen essentiell. Die vorliegende Arbeit dient folglich der Entwicklung eines 
einfachen und schnellen Verfahrens zur Bestimmung der Plasmaproteinbindung von 
Missbrauchsdrogen, insbesondere von neuen psychoaktiven Substanzen. 
 
Methodik:  Das Ausmaß an Plasmaproteinbindung wurde mithilfe von Ultrafiltration 
und Flüssig-Chromatographie mit Massenspektrometrie-Kopplung der ungebundenen 
Fraktion ermittelt. Alle Experimente wurden unter Verwendung von Millipore Centrifree 
zwei-Kammer-Ultrafiltrationseinheiten mit semipermeabler Membran und einem Agilent 
MSD zur massenspektrometrischen Analyse nach erfolgter Stofftrennung durch 
Umkehrphasen-Flüssig-Chromatographie durchgeführt. Nach Zentrifugation erfolgte 
die Probenaufbereitung durch Proteinfällung mit Azetonitril. Als interner Standard für 
alle Analyten wurde Codein benutzt. Die chromatographische Auftrennung wurde durch 
Gradientenelution mit Ammoniumformatpuffer und Azetonitril erreicht. Die Bestimmung 
der Plasmaproteinbindung gelang durch Analyse von sechs gleichen Proben vor und 
nach Ultrafiltration mit einer Ausgangskonzentration jedes Analyten von 5 µM. Lineare 
Kalibrationsgeraden im Konzentrationsbereich von 1-5 µM wurden in Humanplasma 
und Ultrafiltrat erstellt. Das weitere Vorgehen war wie oben beschrieben. 
 
Ergebnisse: Die Plasmaproteinbindung wurde erfolgreich für 15 neue psychoaktive 
Substanzen aus vier verschiedenen Drogenklassen ermittelt. Vertreten sind 
synthetische Cathinone, synthetische Cannabinoide, Research Chemicals und Herbal 
Drugs. Die ermittelten Werte erstrecken sich von 67% für Benzedrone bis >99% für 
WIN 55,212-2. Aufgrund der klinischen Relevanz des Plasmaprotein- 
bindungsverhaltens von Missbrauchsbrogen, kann die vorliegende Arbeit für diesen 
Zweck als einfach realisierbares und sicheres Verfahren in der forensischen und 
klinischen Toxikologie dienen. 
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3 Introduction 
 
3.1 Plasma Protein Binding 
 
Plasma protein binding (PPB) is a decisive factor for the efficacy and toxicology of a 
drug considering the fact that only the unbound drug interacts with the target receptor 
achieving the desired effect (1–4). High binding values to plasma proteins reduce the 
concentration of the free drug in the systemic circulation (5). Furthermore, drug-protein 
complexes serve as drug reservoir and prolong the half-life period, respectively (1,6). 
Volume of distribution, biotransformation, and elimination are based on free drug 
concentration and could result in considerable modifications depending on PPB (5,6). 
In addition, the balance between bound and unbound concentration is affected by 
changes in pH value, temperature, and the concentration of both plasma proteins and 
competitive drugs (4). Alteration in PPB, such as renal or hepatic impairment or 
pregnancy, can lead to acute toxicity (5,7,8). The two predominant binding proteins are 
albumin and α1-acid glycoprotein, whereby albumin represents nearly 60% of the total 
protein in human plasma. Its concentration in plasma is almost constant, but can 
reduce promptly after severe injuries and surgery (4). α1-acid glycoprotein is an acute-
phase-protein generally increasing in infectional and inflammatory diseases (1,4). 
Drug-drug interactions based on competition for the same binding sites result in a 
displacement from bound molecules and an increased blood level of the free drug 
(1,7). This exhibits possible toxicological effects in case of any additional drug use (5).  
 
 
3.2 Novel Psychoactive Substances 
 
In recent research, the term novel psychoactive substances (NPS) is used for occurring 
synthetic drugs of abuse typically designed as chemical derivatives of well-known illicit 
stimulants such as cocaine, amphetamine, or cannabis (9–12). NPS create similar 
pharmacological effects to the drugs they imitate but with the advantage of legal status 
in many states and the ready availability from head shops or the online market sold as 
bath salts or herbal mixtures (9–13). Key reasons for the increasing popularity include 
above all the difficulty of detecting NPS by analysis of biological materials in many 
standard laboratories (11–15). This fact makes newly marketed drugs of abuse 
particularly attractive for persons frequently undergoing drug screenings as it is seen in 
withdrawal clinics (16).  
 
More than 300 different NPS have been synthesized since the beginning of the 
21th century (10–12). In the European Union (EU), researchers have been identifying 
more than one additional designer drug every week due to quick replacement of 
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recently banned drugs by a similar substance on the market (11). NPS are associated 
with higher risk of addiction, overdose, and adverse health effects (10). Because of the 
varying quantities of numerous compounds, found within the marketed product, risk of 
poisoning associated with hospitalization or death, is highly prevalent (12,13,17–19).  
 
Due to the complexity of examining effects drugs of abuse have on humans, 
little human studies with reference to their pharmacology and toxicity exist (8,12,13,15). 
Against the background of the fast identification and quantification of psychoactive 
drugs, a diversity of methods, particularly mass spectrometry (MS), are reported in 
various essays as sensitive and selective (6,7,14,20–22). At present, there is no data 
available on PPB for designer drugs, especially NPS. Therefore, PPB is considered as 
an important parameter to establish safety margins for drug use and was determined 
for 15 NPS representing four different classes (synthetic cathinones, synthetic 
cannabinoids, research chemicals and herbal drugs) to acquire valuable knowledge 
about their distribution, delay of elimination, and acute risk of toxicity. 
 
 
3.3 Spectrum of NPS 
 
3.3.1 Synthetic Cathinones 
 
The naturally occurring alkaloid cathinone is commonly found in shrubs, namely in 
Catha edulis. This type of plant only growing in parts of East Africa and the Arabian 
Peninsula, has been noticed by Europeans because of its psychostimulant effect 
(9,23). Cathinones derive from the phenylethylamine family, only differing in a ketone 
group at the β-position of the amphetamines (9,11,23). Synthetic cathinones are potent 
norepinephrine, serotonin, and dopamine reuptake inhibitors and they are responsible 
for neurotransmitter release (9–11,23,24). Desirable effects are as follows: euphoria, 
increased endurance as well as reduced appetite and need to sleep (9,10,13,14). 
Several synthesized cathinones were patented for therapeutic purposes notably as 
appetite suppressants (9,14). However, with increasing cases of abuse and reports of 
acute toxicity, legal restrictions were enforced and individual derivates were submitted 
to control measures across the EU in 2010 (9). Nowadays, there are approximately 30 
known cathinone derivates (13), found as the main components of so-called bath salts. 
Compared with the non-β-keto amphetamines, synthetic cathinones possess a high 
affinity towards the dopaminergic receptors, thus triggering abuse and addiction (9–11). 
 
Synthetic cathinones can be classified based on their pharmacological 
properties. Five compounds are investigated in this research for their PPB profile (cf. 
Fig.10). Since 2007, mephedrone has been the most frequently found synthetic 
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cathinone available on the European market (9,13). Along with benzedrone, it belongs 
to a class characterized by its activity spectrum similar to cocaine and MDMA (10,11). 
In 2008, the first death caused by the abuse of mephedrone has been confirmed in 
Sweden (9). Methylone is the β-keto derivative of MDMA representing a large group of 
analogues of 3,4,-methylenedioxyamphetamines (9). This compound is known to be 
the main ingredient of the liquid designer drug Explosion (9) and referred to as MDMA-
like entactogens and empathogens, causing altered visual, auditory, and tactic 
perception. Furthermore, MDPV and PVP belong to the widely spread derivates of the 
synthetic cathinone pyrovalerone (11). MDPV is at least 10-fold more potent compared 
with cocaine (25). Acute toxic effects are predominantly related to the potent 
stimulation of the catecholaminergic system (23). Acute psychotic symptoms include 
agitation, epileptic seizures, hallucination, and cardiovascular toxicities (11,23,25). A 
widespread of MDPV has been observed as a recreational drug leading to increasing 
rates of acute intoxication and death, particularly among young adults (23).  
 
 
3.3.2 Synthetic Cannabinoids 
 
Synthetic cannabinoids (SC) consist of a huge and fast growing class of NPS 
characterized by their high affinity to the CB1 receptor (11) and marketed as legal 
alternatives to D9-tetrahydrocannabinol (D9-THC) (21). Herbal cannabis is extensively 
consumed because of its psychotropic potentials such as euphoria, intensified 
perception, and increasing appetite. SC have primarily been designed in research 
centers in order to explore the endocannabinoid pathway (22,26). Considering the 
spread of SC in herbal mixtures, they have rapidly developed into recreational drugs 
(22). Being a group of over 50 known compounds with different structures (22), SC 
operate as potent cannabinoid receptor agonists with mostly stronger CB1 binding 
affinity and higher analgesic potency than other cannabinoids (11,17,22). On the other 
hand, the misuse of SC commonly results in agitation, tachycardia, chest pain, and 
nausea and specifically acute psychosis and paranoia (22). Severe toxicity includes 
seizures, hallucinations, hypokalemia, and acute kidney failure (11,18,22). Seven 
frequently misused SC representing agents of three significant chemical families are 
investigated for their affinity to plasma proteins. They include the naphhoylindoles, 
benzylindoles and indazole-carboxamides (cf. Fig. 11).   
  
Most SC are named JWH which derives from the initials of Dr. John William 
Huffmann, who synthesized numerous psychotropic cannabinoids according to the 
family of aminoalkylindoles in 1994 (10,22). Being an integral part of more than 60 
different drug brands in Germany (18), JWH-018 was the first identified compound in 
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the herbal mixture named Spice (10). JWH-018 structurally differs from JWH-210 and 
AM-2201 to a lesser extent. It is one of the most potent naphthoylindole-derivates 
leading to strong mental and physical effects and high risk of intoxication (18,22). AM-
2201 was synthesized to undergo common drug screenings after having achieved 
detectability of JWH-018 in urine samples (16). Research proves that the combination 
of alkyl substituents at C2 of the indole with bicyclic aroyl groups is responsible for an 
increase of cannabinoid potency (27). JWH-200, a further representative of the 
naphthoylindole-family is one of the first synthesized SC of its kind providing a more 
complex composition. With the intention to investigate numerous derivates of the 
aminoalkylindoles, the Winthrop group synthesized miscellaneous SC including WIN 
55-212,2 (27). As shown by Meyer et al., JWH-200 and WIN 55-212,2 were both 
identified as potent inhibitors of p-glycoprotein (P-gp) (28). In contrast, RCS-4 and AB-
PINACA-5F both vary from the reported basic structure of the naphtoylindole family. In 
order to compare the interaction with plasma proteins between different chemical types 
of SC, the described compounds are studied in the following experiments.   
 
 
3.3.3 Research Chemicals 
 
So-called research chemicals are created in common laboratories for pharmacological 
and therapeutic purposes, but are widely misused as recreational designer drugs with 
typically hallucinogenic properties. Two significant structural families of hallucinogens 
and their synthesized derivatives exist: indolamines and phenylalkylamines (12) (cf. 
Fig.12). 25I-NBOMe was developed by Ralf Heim at the University of Berlin as potent 
agonist for 5-HT2A serotonin receptors with hallucinogenic activity in 2003 (19). 25I-
NBOMe belongs to the chemical family of 2,-5-dimethoxyphenethylamines, called the 
2C compounds whereof 25I-NBOMe has been one of the most potent compounds 
since 2012 (11,19). Its abuse has been attributed to severe serotonergic-, but also to 
sympathomimetic intoxications (11) as well as death cases mostly caused by overdose 
due to its extremely low microgram dosage (19). 5-MeO-DALT is part of the huge class 
of hallucinogenic tryptamines synthesized by the chemist Alexander Shulgin in 2004 
(12). Tryptamines contain an indole nucleus as basic structure combined with an 
ethylamine group (11). Hallucinogenic tryptamines have high structural similarities with 
serotonin and a high affinity for the serotonin 5-HT2A receptor (12). The indole nucleus 
has proven to be responsible for the hallucinogenic properties (12). Slight alterations of 
the chemical structure lead to new substances with more powerful psychoactive effects 
(12). Up until today, about 50 novel synthetic tryptamines have been known for their 
common misuse and as a substitute for traditional hallucinogens (12). All 
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hallucinogenic tryptamines produce changes in visual perception, feeling of unreality, 
and depersonalization provoking psychotic panic reactions (12). Acute toxic effects 
include severe agitation, excited delirium, anterograde amnesia, and catalepsy. The 
consumption of 5-MeO-DALT is only outlawed in a few countries around the world (12).      
 
 
3.3.4 Herbal Drugs 
 
Herbal drugs span a wide range of recreational drugs obtained from psychoactive 
alkaloids. Representatives are legally marketed despite causing addiction and cognitive 
impairments (29–31). Glaucine is the main component of Glaucium flavum (yellow horn 
poppy) of the Papaveraceae family growing in Western Europe, North America and 
Asia, as well as therapeutically used as cough suppressant in Bulgaria and neighboring 
countries (31). It is known to exhibit a wide spectrum of pharmacological activities as it 
acts as a PDE4 inhibitor and calcium channel blocker as well as central dopamine D1 
and D2 receptor antagonist (31). Furthermore, Glaucine possesses a high inhibitory 
potential on P-gp comparable with verapamil (28). This might cause serious 
interactions with simultaneously administered drugs as glaucine decreases the efflux 
ratio of P-gp and, as a consequence, increases bioavailability of P-gp substrates (28). 
Likely misused as recreational drug, consumption of Glaucine is accompanied by 
increasing cases of toxicity including hallucinations and dissociative-type symptoms 
(31).  
 
 
3.3.5 Aims of the Present Study 
 
1) Establishing an easy and quick technique for determination of PPB 
2) Verification of the technique with positive control compounds 
3) Determination of PPB of 15 NPS 
4) Comparison of binding affinity between the respective groups of NPS 
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4 Experimental Procedures 
 
4.1 Chemicals and Reagents 
 
PVP (1-phenyl-2-pyrrolidin-1-ylpentan-1-one) was purchased from Pierce Kavanagh, 
Ph.D., Trinity Centre of Health and Science (Dublin, Ireland). MDPV (1-(1,3-
benzodioxol-5-yl)-2-pyrrolidin-1-ylpentan-1-one) was provided by LGC Standards 
GmbH (Wesel, Germany). Methylone ((2R)-1-(1,3-benzodioxol-5-yl)-2-(methylamino) 
propan-1-one) was purchased from Israel Police HQ (Jerusalem, Israel) for research 
purposes. All other investigated synthetic cathinones were obtained from commercial 
suppliers. These include mephedrone ((2S)-2-(methylamino)-1-(4-methylphenyl) 
propan-1-one), and benzedrone (2-(benzylamino)-1-(4-methylphenyl)-propan-1-one). 
JWH-018 (naphthalen-1-yl-(1-pentylindol-3-yl) methanone), JWH-210 ((4-ethyl-
naphthalen-1-yl)-(1-pentylindol-3-yl)methanone), JWH-200 ([1-(2-morpholin-4-ylethyl) 
indol-3-yl]-naphthalen -1-ylmethanone), RCS-4 ((4-Methoxyphenyl)(1-pentyl-1H-indol-
3-yl)methanone) and AM-2201([1-(5-fluoropentylindol-3-yl]-naphthalen-1-ylmethanone) 
were provided by LGC Standards GmbH (Wesel, Germany). WIN 55,212-2 mesylate 
(purity 99%) ((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-
benzoxazin-6-yl)(1-naphthalenyl) methanone ) was purchased from THC Pharm GmbH 
(Frankfurt am Main, Germany). AB-PINACA-5F (N-[(2S)-1-amino-3-methyl-1-oxobutan-
2-yl]-1-(5-fluoropentyl)-indazole-3-carboxamide) was obtained from Prof. Dr. rer. nat. 
Dipl.-Chem. Volker Auwärter, Institut für Rechtsmedizin (Freiburg, Germany). 25I-
NBOMe (2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl-)methyl]ethanamine) 
was purchased from LGC Standards GmbH (Wesel, Germany). 5-MeO-DALT (N-[2-(5-
methoxy-1H-indol-3-yl)-ethyl]-N-prop-2-enylprop-2-en-1-amine) was provided by Dr. 
Simon Brandt (Liverpool John Moores University, UK). Glaucine ((6aS)-1,2,9,10-
tetramethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline) was obtained 
from Oskar Tropitzsch GmbH (Marktredwitz, Germany). Water was purified in the 
authors’ laboratory using a Millipore filtration unit.  All other chemicals and reagents 
were from E. Merck (Darmstadt, Germany) and they were of analytical grade.  
 
 
4.2 Ultrafiltration Conditions 
 
PPB was investigated using two-chambered Centrifree ultrafiltration devices purchased 
from Merck Millipore (Darmstadt, Germany). Experimental conditions were adapted 
from Fung et al. (32) and modified as described below. Each unit consisted of a low-
adsorptive hydrophilic membrane and an O-ring between a sample reservoir on the top 
and a removable filtrate cup on the base. The filter consisted of Ultracel PL 
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regenerated cellulose membranes with a diameter of 14 mm and an active membrane 
surface of 0.92 cm2. The human plasma samples containing the dissolved drug were 
transferred to the upper chamber. Accelerated through ultracentrifugation, the sample 
was soaked through the filter chosen to let only the unbound drug pass. Larger 
molecules as the protein bounded compound were retained and strict separation 
between the protein-free ultrafiltrate and the protein bound compound was finally 
achieved. The molecular weight cut-off amounted to 30 kDa. The recommended 
sample volume was up to 1000 μL and for the best results it was required to operate at 
relative centrifugal force of 1000-2000 x g1. 
 
 
4.3 Liquid Chromatography Conditions 
 
Reversed phase liquid chromatography (LC) based on modified silica gel was applied 
to attain separation of the substances to be analyzed. The altered sorbent was 
characterized by its nonpolar nature through the use of octyl chains as functional 
group. The applied Superspher® 60 RP-select B spherical porous microparticles with a 
particle size of 4 µm were packed into a Merck LiChroCART column (125 mm × 2 mm 
internal diameter) and a pre-connected LiChroCART 10–2 Superspher 60 RP Select B 
guard column. The mobile phase consisted of 50 mM ammonium formate (3.15 g/L) 
adapted to pH 3.5 with formic acid (eluent A) and acetonitrile containing 1 mL/L formic 
acid (eluent B). After de-gassing, the mobile phase was moved by a pump with a 
maximal pressure limit of 400 bars while keeping a flow rate of 0.4 ml/min. The 
temperature was set at 25°C and the injection volume was 10 μL. Chromatographic 
separation was achieved according to the retention time of each compound in the 
stationary phase and the speed of desorption in the eluent mixture. During the analysis 
the gradient was programmed as listed in Table 1. Table 2 shows the modified gradient 
used for chromatographic separation of methylone and mephedrone demonstrating a 
very close retention time to codeine in the standard settings.  
 
Tab. 1 Standard LC-Timetable with indication of ratio of eluent B, %, flow rate and maximal     
pressure (MaxP) at the relevant time, minutes. 
 
Time %B Flow MaxP 
0.00 40 0.400 400 
4.00 40 0.400 400 
4.01 90 0.600 400 
7.00 90 0.600 400 
7.01 40 0.400 400 
10.00 40 0.400 400 
                                               
1 Based on the recommendation of Centrifree Ultrafiltration Devices (User Guide). 
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Tab. 2 LC-Timetable applied for mephedrone and methylone 
 
Time %B Flow MaxP 
0.00 1.0 0.700 400 
0.50 1.0 0.700 400 
3.00 30 0.700 400 
4.50 30 0.700 400 
5.00 40 0.700 400 
5.01 99 0.700 400 
6.00 99 0.700 400 
6.01 1.0 0.700 400 
9.00 1.0 0.700 400 
4.4 LC-MS Conditions 
 
The samples were quantified using an Agilent Technologies (AT, Waldbronn, 
Germany) AT 1100 series LC-MSD, SL version, defined as a quadrupole based 
atmospheric pressure chemical ionization (APCI) instrument and controlled by LC-MSD 
ChemStation using the A.08.03 software. The general conditions were adapted 
according to Maurer et al. (33). APCI is characterized by direct and continuous transfer 
of the liquid sample into vapor phase while maintaining atmospheric pressure (34). 
Therefore a unity of pneumatic nebulizer and heated spray chamber with a fine needle 
electrode was applied as ion source. Device setup comprised the following:  
 
Drying gas: nitrogen (7000 mL/min, 300°C); nebulizer gas: nitrogen (25 psi, 172.3 kPa); 
vaporizer temperature: 400°C; capillary voltage: 4000 V; corona current: 5.0 mA; 
fragmentor voltage: 100 V.  
 
A solution comprising the analyte was injected in hot nitrogen current to 
vaporize the solvent. Ion generation was achieved by corona discharge between the 
needlepoint and spray chamber in counter electrode function. The analytes were 
identified and quantified by the selected ion monitoring (SIM) mode using ions at the 
respective m/z (M+H) +. GraphPad Prism 5 (GraphPad Software Inc., San Diego, 
California) was used for calculating descriptive statistics and linear regression models. 
Quantification was performed using an unweighted linear regression model. Calibration 
curves were constructed plotting peak area ratios (analyte against codeine, m/z 300) of 
spiked calibrators both in human plasma (1, 2, 3, 4, and 5 μM) an ultrafiltrate (1, 2, 3, 4, 
and 5 μM) versus their concentrations. As the class of SC suggested high PPB with 
regard to THC, their calibration model in ultrafiltrate was selected to range from 0.2-1 
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μM. MS response peak area ratios (NPS against IS) versus concentration were plotted 
to obtain calibration curves. 
 
 
4.5 Study Design 
 
4.5.1 Calibration Standards in Human Plasma and Ultrafiltrate 
 
All tested NPS were prepared as a 10 μM initial pure substance solution whereof a 
solution series in the concentration range of 1-5 μM was done both in blank human 
plasma and blank ultrafiltrate. At first, spiked human plasma was incubated in 1.5 ml 
Eppendorf tubes for 30 minutes at 37°C in a compact thermo shaker. Protein 
precipitation was achieved by diluting 100 μL of the spiked samples with 200 μL 
acetonitrile (2M) und 100 μL ammoniumacetate (2M). As internal standard (IS), 
codeine dissolved in acetonitrile was used at a final concentration of 2 μM. At 1680 
rpm, the tubes were vortexed and centrifuged for 90 seconds. Thereafter, 100 μL of the 
clear supernatant were transferred to glass microvials and analyzed by LC-MS. 
Reverse phase liquid chromatographic separation was achieved using a gradient 
elution of ammonium formate buffer and acetonitrile. Calibration curves were 
constructed using MS response peak area ratios (analyte/codeine) against the target 
concentration. A straight-line equation (y=m*x) for calibration was calculated for all 
investigated compounds in human plasma using concentration levels from 1-5 μM. To 
generate the ultrafiltrate, 500 μL of human plasma (n=6) were added to Centrifree-
devices and centrifuged for 30 min at 3000 rpm. The thus gained ultrafiltrate in each 
device was spiked with the analyte in order to obtain a concentration range of 1-5 μM.  
A volume of 100 μL of the spiked ultrafiltrate was treated as described above for 
determination of calibration curves in ultrafiltrate. 
 
 
4.5.2  Sample Preparation for PPB Studies 
 
PPB was investigated by comparison of drug concentrations prior and after 
ultrafiltration. Six replicates of human plasma (500 μL) spiked with the tested 
compound at a defined concentration of 5 μM after incubation were split into two 
different test series, respectively. A control series was prepared by vortexing and 
centrifuging 100 μl of each sample treated previously with acetonitrile for protein 
precipitation and spiked with the IS as described above. The six human plasma 
samples were analyzed via LC-MS by integration of the desired fragment ions and 
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applying the established human plasma calibration equation in order to verify the initial 
concentration of 5 μM. 
 
To determine the PPB on the basis of the free drug concentration in ultrafiltrate, 
400 μl of the incubated samples were centrifuged in Centrifree devices as described 
above. 100 μl of the thus gained ultrafiltrate in each device were prepared similarly to 
the control and calibration series and transferred to glass vials to be analyzed by LC-
MS. The unbound concentration was directly calculated based on MS response area 
ratios applied to the ultrafiltration calibration equation made for each tested compound. 
To calculate the unbound fraction, the total concentration of the respective compound 
in human plasma was added to the relation and PPB could be determined according to 
the following equation: 
 
PPB (%) = (1-( 
C UF
C HP
 ))* 100 
C UF =  Drug concentration in ultrafiltrate (μM) 
C HP =  Drug concentration in human plasma (μM) 
C UF
C HP
 = Ratio of unbound tested drug 
 
To double check the results, the concentration of the retained volume in the Centrifree 
devices was determined in the same way for any tested drug. The applied method was 
verified as follows:  
 
C UF + C RV = 5 μM 
C UF = Drug concentration in ultrafiltrate (μM) 
C RV = Drug concentration in retained volume (μM) 
 
All experimental steps were verified using representatives of drugs with already 
existing PPB values in literature (22,35,36). PPB studies on sertraline, cimetidine, DOI, 
butylone, and THC were performed to assure that the applied method was sensitive 
and reliable for the provided study. 
 
 
5 Results 
 
5.1 Chromatographic Separation  
 
Chromatographic separation was achieved according to the retention time of each 
compound in the stationary phase and the speed of desorption in the eluent mixture. 
The eluting power of the mobile phase rose with decreasing polarity by augmenting the 
concentration of the stronger eluent B during the separation process. In order to 
achieve strictly separated signals of drug and IS, the gradients of eluent A and B during 
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the separation process were programmed as already described. A new gradient was 
needed for methylone and mephedrone, which showed a very close retention time to 
codeine in the standard setting. By increasing the flow rate and rapid increase of eluent 
B in gradual steps, well separated and sharp signals could be obtained as shown in 
Figure 2. The analytes were quantified by the SIM mode using the protonated 
molecular ions at m/z (M+H) +. These m/z were found to be selective and provided the 
most intense signal in the mass spectrometer. The respective target ions and retention 
times obtained by LC-MS are summarized in Table 4. Representative chromatograms 
for the two applied LC-MS settings are shown in Figures 1 and 2 exemplified for 
synthetic cathinones at a concentration of 2 μM in the ultrafiltrate. Retention times are 
given on the abscissa whereas the y-values depend on the respective ion abundance 
at this point.  
 
 
  
Fig. 1 Representative LC-MS-chromatograms of synthetic cathinones and internal 
standard (IS) obtained by standard LC-setting and quantification in SIM-mode 
using m/z-: 232 (PVP); 254 (benzedrone); 276 (MDPV); 300 (codeine, IS). 
The chromatograms are of 2 μM of the calibrator in ultrafiltrate 
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Fig. 2 Representative LC-MS-chromatogram obtained by the modified 
LC-setting optimized for methylone and mephedrone 
m/z-: 178 (mephedrone); 208 (methylone); 300 (codeine, IS). The 
chromatogram is of 2 μM of the calibrator in ultrafiltrate 
 
 
 
 
 
 
 
Tab. 3 NPS with corresponding formula and exact masses, targeted ions 
in the SIM mode and retention time (RT) recorded by LC-MS 
 
 
  
NPS Formula 
Exact mass, 
g/mol 
SIM Ion RT, min 
Mephedrone C11H15NO 177.12  178 6.3  
Methylone  C11H13NO3 207.09   208 5.5 
Benzedrone C17H19NO 253.15  254 0.9 
MDPV  C16H21NO3 275.15 276 1.7  
PVP     C15H21NO 231.16 232 1.7  
     
JWH-018     C24H23NO 341.18 342 7.1  
JWH-210     C26H27NO 369.21 370 7.2 
AM-2201  C24H22FNO 359.17  360 6.7  
JWH-200  C25H24N2O2 384.18 385 3.5  
WIN-55,212-2  C27H26N2O3 426.19 427 6.6  
RCS-4 C21H23NO2 321.17   322 6.6  
AB-PINACA-5F    C18H25FN4O2 348.19 349 4.8  
     
25I-NBOMe  C18H22INO3 427.06 428 4.7  
5-MeO-DALT C17H22N2O 270.17 271 1.7  
     
Glaucine C21H25NO4 355.18 356 1.4  
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5.2 Method Verification 
 
The experiments were first performed using five positive control compounds (n=6) with 
already known PPB (22,35,36). The selected values range from 15% to 97% thus 
covering low, medium, and high PPB. Table 3 shows experimental means ± standard 
deviation of all tested compounds. The 95% confidence intervals (CI) of the means 
were within 80-110% of the respective target values taken from literature (22,35,36). 
Accuracy and precision data were both within the acceptance interval of 15% for the 
five positive control compounds; except for cimetidine showing a relative standard 
deviation (RSD) exceeding the accepted limits of 15%.  
 
 
Tab. 4 Comparison of PPB between experimental data (n=6) and data sources available in the literature 
Indication of 95% CI (95% confidence interval of the mean); RSD (Relative standard deviation); 
References are given in parenthesis 
 
Drug 
Theoretical 
PPB 
Experimental 
PPB 
95% CI RSD Bias 
Butylone 57% (35) 57%± 8.2 47-66% 14.5% 0% 
Cimetidine 15-20% (36) 17%± 3.5 13-21% 20% 0% 
Sertraline 99% (35) 97%± 0.7 96-98% 0.8% 2% 
DOI 65-79% (35) 61%± 8.7 51-70% 14.5% 4% 
THC 97% (22) 97%± 0.3 96-97% 0.4% 0% 
 
 
 
5.3 Calibration Model 
 
An unweighted linear regression model was applied to all studied drugs. Figures 3-7 
show the best fitting linear regression line and the respective straight-line equation 
(y=m*x) for all drugs. The coefficient of determination between measured and 
calculated data values exceeded 0.98 for all drugs both in plasma and filtrate indicating 
a well fitting of the linear regression lines. Accuracy and precision in the range of 1-5 
μM were established based on the fact that all measured concentrations deviated less 
than 10% from the target concentrations. 
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Calibration curves of synthetic cannabinoids in human plasma 
Fig. 4 Calibration curves of synthetic cannabinoids in the concentration range from 1-5 μM in human plasma 
X-axis: concentration, μM / Y-axis: Peak area ratio, NPS/IS 
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Calibration curves of synthetic cannabinoids in ultrafiltrate 
Fig. 5 Calibration curves of synthetic cannabinoids in the concentration range from 1-5 μM in ultrafiltrate 
X-axis: concentration, μM / Y-axis: Peak area ratio, NPS/IS 
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Calibration curves of research chemicals in human plasma 
Calibration curves of research chemicals in ultrafiltrate 
Fig. 6 Calibration curves of research chemicals in the concentration range from 1-5 μM in human 
plasma (1) and ultrafiltrate (2) X-axis: concentration, μM / Y-axis: Peak area ratio, NPS/IS 
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Calibration curves of herbal drugs in human plasma 
Calibration curves of herbal drugs in ultrafiltrate 
Fig. 7 Calibration curves of herbal drugs in the concentration range from 1-5 μM in human plasma (1) 
and ultrafiltrate (2) X-axis: concentration, μM / Y-axis: Peak area ratio, NPS/IS 
 
0 1 2 3 4 5
5
10
15
20
Glaucine
9979.0
)055.0313.4(
2 

R
xy
concentration, M
P
e
a
k
 a
re
a
 r
a
ti
o
21 
 
5.4 Plasma Protein Binding Studies 
 
Six replicates of each analyte with an initial concentration of 5 μM in human plasma 
were measured first as control series and, after ultrafiltration, for determination of PPB 
in ultrafiltrate and retained volume. Column graphs of the sextuple measured drug 
concentration in ultrafiltrate and supernatant of all 15 NPS are shown in Figure 8. The 
respective mean values are outlined in italics in each graphic. The sum of the 
calculated mean values of each analyte in ultrafiltrate and supernatant did not differ 
from 5 μM by more than 10%, respectively. Coefficients of variation never exceeded 
15% in the concentration range from 1-5 μM and 20% in the lower concentration range 
from 0.2-1 μM in ultrafiltrate. The measured values in the control series covered the 
initial concentration of 5 μM within the 95% confidence interval. Corresponding 
statistical parameters of the control series are given in Tables 5-8. Mean values, 
standard deviation, and coefficient of variation are reported. All data values were tested 
on statistical significant outliers performing Grubb`s test with a significance level of 
α=0.05. Identified outliers were excluded from calculations of PPB. The dispersion of 
the values highly depended on the applied matrix noticing a greater deviation of the 
replicates in supernatant compared with the same measurements in ultrafiltrate.  
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Fig. 8 Column graphs of experimentally determined concentrations of the 
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Statistical parameters of experimental data obtained in human 
plasma; n=6 Indication of mean, standard deviation (SD), coefficient 
of variation (CV) 
Statistical parameters of experimental data obtained in human 
plasma; n=6 Indication of mean, standard deviation (SD), coefficient 
of variation (CV) 
Statistical parameters of experimental data obtained in human 
plasma; n=6 Indication of mean, standard deviation (SD), coefficient 
of variation (CV) 
      Tab. 5 Synthetic cathinones- Control Series 
       
 
 
 
 
        
 
 
 
 
 
 
 
      Tab. 6 Synthetic cannabinoids- Control Series 
                         
 
 
 
Drug Mean SD CV 
JWH-018 5.3 0.6 12  % 
JWH-210 5.3 0.3 6.2 % 
AM-2201 5.2 0.3 5.1 % 
JWH-200 5.2 0.5 9.3 % 
WIN-55,212-2 4.9 0.5 9.5 % 
RCS-4 5.0 0.2 4.3 % 
AB-PINACA-5F 5.1 0.7 14  % 
 
 
      Tab. 7 Research chemicals- Control Series 
           
 
 
 
 
 
 
 
 
 
 
       Tab. 8 Herbal drugs-Control Series 
 
 
 
 
 
Drug Mean SD CV 
Glaucine 5.2 0.4 8.5 % 
 
 
 
 
        
 
Drug Mean SD CV 
Mephedrone 4.8 0.1 2.9 % 
Methylone 4.9 0.0 0.8 % 
Benzedrone 5.5 0.4 6.7 % 
MDPV 4.3 0.2 4.1 % 
PVP 4.8 0.7 13  % 
Drug Mean SD CV 
25I-NBOMe 5.6 0.3 4.7 % 
5-MeO-DALT 5.1 0.3 5.6 % 
Statistical parameters of experimental data obtained in human 
plasma; n=6 Indication of mean, standard deviation (SD), 
coefficient of variation (CV) 
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6 Discussion 
 
6.1 Significance of the Present Study 
 
PPB of drugs is considered to be an important parameter in forensic toxicology as free 
drug concentrations in body fluids are regulated by protein binding (8). Solely the 
amount of free drug is detectable in drug-screening tests and moreover crucial for the 
management of poisoned patients considering the possibility of detoxification therapy 
(e.g. hemodialysis) only for drugs with a low degree of PPB. Due to the significance of 
establishing precise PPB values especially for NPS, a sensitive and well practicable 
technique has been developed.  
 
 
6.2 Method Development 
 
The method used in the present study turned out to determine reliable data of PPB up 
to bound fractions of nearly 100%. All investigated NPS showed affinity to plasma 
proteins with corresponding results in ultrafiltrate and supernatant. It should be noted 
that the extent of standard deviations was dependent of the used matrix. The standard 
deviations were always higher in the supernatant. Ultrafiltrate is considered to achieve 
the most precise measurements. The applied procedure has been found to be suitable 
for concentrations of 5 μM, which was chosen to cover expected ranges of drug 
concentrations in body fluids.  
 
There are various methods of isolating the unbound fraction in human plasma 
samples. In several studies, ultrafiltration is reported as a simple, quick, and safe 
technique in contrast to the most common alternatives such as equilibrium dialysis and 
ultracentrifugation (3–5,37). Regenerated cellulose membranes are confirmed to affect 
experimental studies to a lesser extent by nonspecific adsorption than polyethersulfone 
and modified polyethersulfone membranes (2,4,5,37). An initial volume of 500 μL of the 
dissolved drug centrifuged for 30 min was used to obtain a sufficient amount of 
ultrafiltrate in the shortest possible time. Different ranges of centrifugation time were 
proven not to impact the resulting unbound drug concentration as reported elsewhere 
(4). In addition, a different range of gained ultrafiltrate volume has been experimentally 
verified not to change the equilibrium of unbound and bound drug above the filter 
(4,37). The pH values were checked to ensure accepted ranges of 7.35-7.45 prior to 
each experimental procedure. The subsequent analytical step using LC-MS was a 
sufficient method to identify and quantify the unbound drug. APCI was chosen as soft 
ionization method based on positive-ion chemical ionization (34). Due to the 
multidimensional information of the MS presented in signal intensity, mass-to-charge 
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ratio and chromatographic retention time, all drugs have been determined quickly and 
clearly. The SIM mode was sufficient to give the most abundant peak signal according 
to the mass-to-charge ratio (m/z) using ions at the parent m/z (M+H) +. Codeine turned 
out as confident and stable IS without any remarkable drug interferences in the applied 
chromatographic program.  
 
 
6.3 Correlation between PPB and Lipophilicity 
 
PPB  is commonly associated with physicochemical properties of a drug besides 
spatial configuration and intermolecular interactions between plasma proteins and 
drugs (1). This suggests that the extent of PPB is closely linked to the chemical profile 
of a drug considering little changes in the chemical composition leading to modified 
extents of PPB. Moreover, it might be assumed that represents of the same drug class 
exhibit similar extents of PPB. This relationship is further examined in the discussion of 
PPB results within the respective drug classes below. According to Kratochwil et al., 
lipophilicity is the most commonly accepted parameter used for prediction of PPB 
affinity (1). In order to investigate the correlation between PPB and lipophilicity, log P 
values were used as a valid measure for lipophilicity (27). This parameter outlines the 
distribution of the unionized drug between the aqueous and organic phase. In Figure 9, 
the corresponding log P values for each investigated compound have been taken from 
literature (PubChem Database) and were plotted against the experimentally 
determined PPB values for all 15 NPS (38). Linear correlation was calculated using the 
Pearson correlation coefficient which was r = 0.8. This result implies a significant 
correlation between PPB and lipophilicity for the tested compounds (significance level 
of α=0.05).   
  
29 
 
0 1 2 3 4 5 6 7
60
70
80
90
100
JWH-
210
JWH-
018AM-
2201
RCS-4
WIN-55,
212-2
JWH-200
Benzedrone
25I-NBOMe
Methylone
Mephedrone
MDPV
Glaucine
PVP
5-MeO-
DALT
AB-PINACA
-5F
logP
P
P
B
, 
%
 
Fig. 9    Correlation between log P (x-axis) and PPB, % (y-axis) for all investigated NPS 
 
 
6.4 Distribution of PPB-Results within the Classes of NPS 
 
6.4.1 Synthetic Cathinones 
2 
 
The five investigated synthetic cathinones show intermediate PPB levels ranging from 
59% to 77% (cf. Tab.9). Their chemical profiles differ in substituents of the amino group 
(R2) and the benzyl ring (R3) as demonstrated in Figure 10. Mephedrone provides a 
                                               
2 BIOVIA Draw 2016 was used to create all following structural formulae 
Fig. 10 Chemical structures including a generic structure of  
the five investigated synthetic cathinones  
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chemical structure closest to the natural cathinone. It is characterized by simple 
methylation of the primary amino group and a further ring-substitution of a methyl group 
in para position. By addition of a benzyl ring to the methyl residue of the secondary 
amino group, a more complex and more lipophilic compound is created. Benzedrone is 
rather bound to plasma proteins than mephedrone as previously derived. A further 
subtype of cathinone derivates is represented by methylone containing a 
methylenedioxy group at R3. Due to the polarizing effect of this functional group, 
methylone has less lipophilic properties, expressed as well in a lower extent of PPB. 
MDPV is characterized by the heterocyclic pyrollidine leading to a tertiary nitrogen 
atom. Its chemical structure includes furthermore the 3,4-methylenedioxy group like 
methylone. The tertiary amino group leads to a more lipophilic molecule resulting in 
higher blood–brain barrier permeability than other cathinone derivates (23) and an 
increasing PPB. PVP provides a chemical composition similar to MDPV only differing in 
the not substituted benzyl ring. Consequently, PVP shows the highest lipophilicity of all 
five derivates, resulting furthermore in the strongest binding to plasma proteins.  
 
 
Tab. 9 Experimental results of PPB in ultrafiltrate (UF) and supernatant (SN) pointed out 
for the class of synthetic cathinones  
 
Drug PPB - UF PPB-SN 
Mephedrone 64% (61-67) 62% (51-71) 
Methylone 59% (58-61) 69% (65-73) 
Benzedrone 63% (59-67) 57% (46-68) 
MDPV 72% (69-75) 70% (66-74) 
PVP 77% (75-79) 80% (75-85) 
 
  
31 
 
6.4.2  Synthetic Cannabinoids 
 
 
 
Tetrahydrocannabinol (THC) as the principal compound in cannabis is known to be 
highly bound to plasma proteins based on  literature values of 97% (6). Its chemical 
structure is derived from the class of aromatic terpenoids. Cannabinoids in general are 
known to be strongly lipophilic and thus present a long elimination half-life compared to 
other recreational drugs. The class of SC shows PPB levels close to 100% (cf. Tab. 
10). As demonstrated in Figure 11, all compounds, except for AB-PINACA-5F, possess 
a naphthoylindole group as chemical basic. Characteristically, the indole nitrogen is 
linked to an aryl group resulting in a tertiary nitrogen atom with strongly lipophilic 
properties. Besides, aminoalkylindoles act as effective CB1 agonists with much higher 
analgesic potency than other cannabinoids (22,27). JWH-018, JWH-210 and AM-2201 
exhibit binding values of 99% in the experimental studies and show a high degree of 
similarity regarding their chemical pattern. JWH-018 is characterized by a pentyl group 
linked to the indole nitrogen which is attributable to enhance the psychotropic effects 
(27) as JWH-018 is 3.4-fold more potent than THC (18). JWH-210 is only differing from 
Fig. 11 Chemical structures of the investigated synthetic cannabinoids 
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Tab.  10 Experimental results of PPB in ultrafiltrate (UF) and supernatant (SN) pointed 
out for the class of synthetic cannabinoids  
 
      
 
 
JWH-018 by substitution of an ethyl group at C-4 of the naphthalene providing once 
again an increase in CB1 receptor affinity (27). AM-2201 is the fluorinated analogue of 
JWH-018 possessing equal psychotropic properties as well as affinity to plasma 
proteins. JWH-200 exhibits a more complex functional group linked to the indole 
nitrogen. First of all, WIN 55,212-2 distinguishes from the compared SC in a methyl 
residue at the indole group and moreover a modified morpholinyl substitution at the 
indole nitrogen. The thus gained complex spatial configuration indicates a great fit for 
human plasma proteins. RCS-4 possesses a methoxyphenyl ring instead of the 
naphthoyl group in its basic structure resulting in no significant differences in the affinity 
of PPB. AB-PINACA-5F provides the most significant modifications in the chemical 
composition with regard to the family of SC. This compound differs from all other 
investigated SC in the indazole nucleus linked to an aliphatic fluoropentyl chain and a 
carboxamide derivate. It is the fluorinated analogue of AB-PINACA. In particular, the 
carboxamide groups leads to a polarized and hydrophilic molecule. These structural 
differences are mainly apparent in the significantly lower PPB compared with the 
previous values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Drug PPB - UF PPB-SN 
JWH-018          99% (99-100)         100% (89-100) 
JWH-210          99% (99-100)         99% (94-100) 
AM-2201          99% (99-100)         98% (96-100) 
JWH-200          98% (98- 99)         88% (78- 97) 
WIN-55,212-2          99% (99-100)         90% (78-100) 
RCS-4          99% (99-100)         98% (88-100) 
AB-PINACA-5F          87% (85- 90)         84% (72-96) 
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6.4.3  Research Chemicals 
 
 
 
Fig. 12 Chemical structures of the investigated research chemicals 
 
The two investigated research chemicals originate from two different chemical families. 
25I-NBOMe belongs to the chemical group of 2,-5-dimethoxyphenethylamines, which is 
characterized by addition of methoxy- groups at the 2- and 5-positions of the aromatic 
ring (cf. Fig. 12). This structural modification, as well as the iodation at position 4 of the 
ring, increases the 5-HT2A receptor affinity compared with classic hallucinogens. 
Furthermore, the chemical structure of 25I-NBOMe provides a secondary nitrogen 
atom substituted with a methoxy phenylring. Due to the aromatic ring systems and the 
oxygen substituents with electron donor effects, the molecule acts as a chemically 
stable and lipohilic compound with a high PPB (cf. Tab. 11). 5-MeO-DALT possesses 
an indole nucleus as basic structure linked to an ethylamine group with two attached 
propionyl side chains. The tertiary amino group creates a molecule with high lipophilic 
properties. Furthermore, by introducing an alkylated hydroxyl group at position 5 of the 
aromatic ring, increased permeability of the blood-brain barrier and consequently great 
potency is achieved (12). 5-MeO-DALT provides a high binding affinity to plasma 
proteins in the experimental series. 
 
Tab. 11 Experimental results of PPB in ultrafiltrate (UF) and supernatant (SN) pointed out 
for the class of research chemicals 
 
Drug PPB - UF PPB-SN 
25I-NBOMe 89% (87-91) 85% (80-89) 
5-MeO-DALT 76% (75-78) 71% (67-80) 
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6.4.4  Herbal Drugs 
 
 
 
Fig. 13 Chemical structures of the investigated herbal drugs 
 
Glaucine represents the chemical class of isoquinoline alkaloids containing a 
benzopyridine as basic structure. This functional group is characterized by four 
methoxy units connected to two merged benzene rings. The tertiary amine in the 
piperidine ring leads to a more lipophilic compound. The aromatic system is stabilized 
by the methoxy groups referred to above, acting as free electron pair donors. Due to 
lipophilic basic structure along with the tertiary amine, the experimental findings are 
well corresponding to the structural composition as demonstrated in Table 12. 
Furthermore, the tertiary amino group linked to an aromatic system was accepted as 
essential structural characteristic concerning P-gp interactions (28). Fulfilling this 
criterion, JWH-200, WIN 55,212-2 and glaucine were investigated and identified as 
inhibitors of P-gp causing possible toxic effects by increasing the extent of oral 
absorption of P-gp substrates (28).  
 
                 
    Tab. 12 Experimental results of PPB in ultrafiltrate (UF) and supernatant (SN) pointed out for 
the class of herbal drugs  
 
 
  
 
Summarizing, all NPS display a trend towards high PPB levels. In the separate 
classes, the individual compounds exhibit comparable extents of PPB. It is therefore 
obvious that molecules with closely related chemical structures show a very similar 
tendency of PPB. This is evidenced considering little changes in the basic structure of 
a family class leading to modified values of PPB as underpinned, inter alia, with the 
experimental results of AB-PINACA-5F. 
  
Drug      PPB - UF      PPB-SN 
Glaucine 76.9% (74.9-78.9) 84.6% (78.9-90.3) 
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7 Conclusion 
 
PPB was successfully determined for 15 NPS representing synthetic cathinones, 
synthetic cannabinoids, research chemicals and herbal drugs. Values reaching from 
67% to >99% for the respective drugs were determined indicating a strong tendency of 
high PPB for SC. In addition, the developed method turned out as a fast and simple 
technique practicable in most common forensic and clinical laboratories. Due to the 
importance of the bound ratio of drugs in human blood considering the direct impact on 
important pharmacological parameters, this method could serve as valuable research 
method in prospective screening procedures of novel psychoactive drugs. 
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